Pipeline
Advancing drug candidates with the goal of delivering transformative medicines for patients
Our ReSOLVE™ platform enables a highly differentiated pipeline of small molecule therapeutics for highly validated innate immunity targets. Our lead programs target the inflammasome and nucleic acid sensing pathways. We have multiple programs in discovery and are pursuing a broad pipeline of additional targets.
| Program | Discovery | Lead Optimization | IND-Enabling | Phase 1 |
|---|
| cGAS Franchise | ||||
| VENT-03 Immunology, Inflammation, Dermatology | ||||
| Brain-Penetrant Neuroinflammation, Neurodegeneration | ||||
| Topical | ||||
| Next-Gen Systemic | ||||
| NLRP3 Franchise | ||||
| VENT-02 Neuroinflammation, Neurodegeneration | ||||
| Wholly Owned Systemic Inflammation, Pulmonology | ||||
| VENT-01 Nephrology, Cardiology, Hepatology |  | |||
| Undisclosed | ||||
| Brain-Penetrant Neuroinflammation, Neurodegeneration | ||||
| Systemic Immunology, Gastroenterology | ||||
| Additional Discovery Programs | ||||
We have multiple programs in discovery and are pursuing a broad pipeline of additional targets | ||||
| cGAS Franchise | ||
| VENT-03 | ||
| Immunology, Inflammation, Dermatology | ||
| IND-Enabling | ||
| Brain-Penetrant | ||
| Neuroinflammation, Neurodegeneration | ||
| Lead Optimization | ||
| Topical | ||
| Lead Optimization | ||
| Next-Gen Systemic | ||
| Lead Optimization | ||
| NLRP3 Franchise | ||
| VENT-02 | ||
| Neuroinflammation, Neurodegeneration | ||
| Phase 1 | ||
| Wholly Owned Systemic | ||
| Inflammation, Pulmonology | ||
| Lead Optimization | ||
| VENT-01 | ||
| Nephrology, Cardiology, Hepatology | ||
| IND-Enabling | ||
| Undisclosed | ||
| Brain-Penetrant | ||
| Neuroinflammation, Neurodegeneration | ||
| Lead Optimization | ||
| Systemic | ||
| Immunology, Gastroenterology | ||
| Lead Optimization | ||
Additional Discovery Programs
We have multiple programs in discovery and are pursuing a broad pipeline of additional targets
